Details of the SBP | SYNBIP

General Information of Synthetic Binding Protein (SBP) (ID: SBP000150)
SBP Name	BiTE Pavurutamab
Synonyms	AMG-701; AMG701
Design Method	Traditional methods (Site-directed mutagenesis and/or Directed evolution)
Highest Status	Phase I; Suspended

Protein Scaffold Information of This SBP
Scaffold ID	PS018 Scaffold Info					[1]
Scaffold Name	BiTE
Scaffold Class	Antibody fragment
Fold Type	Beta-Sheets + Loops

Binding Target(s) of This SBP (BTS)

BTS Name	Details	Mechanism	Application	Affinity	Research Organization	Ref
Tumor necrosis factor receptor superfamily member 17	BTS Info	Inhibitor	Prostate cancer [ICD-11: 2C82.Z]; Multiple myeloma [ICD-11: 2A83.Y]	N.A.	Amgen	[1]
T-cell surface glycoprotein CD3	BTS Info	Inhibitor	Prostate cancer [ICD-11: 2C82.Z]; Multiple myeloma [ICD-11: 2A83.Y]	N.A.	Amgen; BeiGene	[1]

Clinical Trial Information of This SBP
NCT03287908	Click to show the Detail
Indication	Relapsed or Refractory Multiple Myeloma
Phase	Phase I
Title	A Phase I/2 Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of?AMG 701?Monotherapy, or in Combination With Pomalidomide, With and Without Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (ParadigMM-1B)
Status	Active, not recruiting
Sponsor	Amgen
NCT04998747	Click to show the Detail
Indication	Relapsed/Refractory Multiple Myeloma
Phase	Phase I
Title	AMG 701 Expanded Access Program
Status	Available
Sponsor	Amgen
NCT05256446	Click to show the Detail
Indication	.
Phase	.
Title	AMG 701 Expanded Access Program
Status	Available
Sponsor	Amgen

References

1

Amgen. Product Development Pipeline. 2021.